Literature DB >> 33493917

The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.

Mohammad Hossain Shariare1, Md Anowar Khasru Parvez2, George A Karikas3, Mohsin Kazi4.   

Abstract

COVID-19 has nowadays affected almost all our societies and global health systems. The latest deadly pandemic has heavily influenced both life and livelihood worldwide. SARS-CoV-2 is the causative organism of COVID-19, that is spreading and infecting significantly higher compared to other coronavirus, due to its constant mutation characteristics. At present although several extensive clinical trials are ongoing, neither approved drug therapy nor any vaccine are available to safely fight SARS-CoV-2. However, a progressive race among numerous research groups to discover a radical cure for the COVID-19 is under way. This review aims to provide an updated insight of the current research, development and trials on repurposing existing drugs and preventive intervention for COVID-19, along with the related issues, complexities and challenges, especially after the observed high transmissibility lately.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  COVID-19; Computational docking; Drug repurposing; SARS-CoV-2; Vaccine

Year:  2020        PMID: 33493917     DOI: 10.1016/j.jiph.2020.12.009

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  8 in total

1.  In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.

Authors:  Shuo Wang; Xuexun Fang; Ye Wang
Journal:  Molecules       Date:  2022-06-30       Impact factor: 4.927

2.  A systematic review of the case findings, testing and management of COVID-19.

Authors:  Dewi Susanna; Dian Pratiwi; Sang Gede Purnama
Journal:  F1000Res       Date:  2021-05-12

3.  Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches.

Authors:  Mingkai Yu; Yuejie Zhu; Yujiao Li; Zhiqiang Chen; Zhiwei Li; Jing Wang; Zheng Li; Fengbo Zhang; Jianbing Ding
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

4.  SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics.

Authors:  Nicholas Hartog; William Faber; Austin Frisch; Jacob Bauss; Caleb P Bupp; Surender Rajasekaran; Jeremy W Prokop
Journal:  Expert Rev Proteomics       Date:  2021-04-05       Impact factor: 3.940

5.  Pineal hormone melatonin as an adjuvant treatment for COVID‑19 (Review).

Authors:  Marilena Vlachou; Angeliki Siamidi; Aikaterini Dedeloudi; Sofia K Konstantinidou; Ioannis P Papanastasiou
Journal:  Int J Mol Med       Date:  2021-02-12       Impact factor: 4.101

Review 6.  The role of antirheumatics in patients with COVID-19.

Authors:  Christoffer B Nissen; Savino Sciascia; Danieli de Andrade; Tatsuya Atsumi; Ian N Bruce; Randy Q Cron; Oliver Hendricks; Dario Roccatello; Ksenija Stach; Mattia Trunfio; Évelyne Vinet; Karen Schreiber
Journal:  Lancet Rheumatol       Date:  2021-03-30

Review 7.  Melatonin, Zinc, and Vitamin C: Potential Adjuvant Treatment for COVID-19 Patients.

Authors:  Leandro Borges; Matheus Gennari-Felipe; Beatriz Belmiro Dias; Elaine Hatanaka
Journal:  Front Nutr       Date:  2022-01-26

8.  Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.

Authors:  Mehul D Patel; Erik Rosenstrom; Julie S Ivy; Maria E Mayorga; Pinar Keskinocak; Ross M Boyce; Kristen Hassmiller Lich; Raymond L Smith; Karl T Johnson; Paul L Delamater; Julie L Swann
Journal:  JAMA Netw Open       Date:  2021-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.